GlassScriptPhysician profile
Eric Andrew Meikle
NPI 1427136563
$1,416.17
in general payments reported to CMS, 2019-2025
22 companies · $233 in 2025
The $233 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $142 · 2021: $56.61 · 2022: $183 · 2023: $163 · 2024: $242 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $319.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $108.56 | 2019-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $91.90 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $91.05 | 2022-2025 | |
| Sobi, INC | $76.39 | 2019-2023 | |
| Kaleo, INC. | $73.77 | 2019-2022 | |
| Baxter Healthcare | $72.22 | 2022 | |
| Alk-Abello, INC | $70.22 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $69.02 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Seqirus USA INC | $49.43 | 2022-2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $48.61 | 2019 | |
| Hologic Sales and Service, LLC | $48.22 | 2024 | Aptima |
| Neuraxis, INC. | $46.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.84 | 2020-2021 | |
| Cranial Technologies, INC | $40.83 | 2024 | Doc Band |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.97 | 2022-2023 | Flumist Quadrivalent |
| Shire North American Group INC | $37.29 | 2019 | |
| Novo Nordisk INC | $23.33 | 2023 | Wegovy |
| Avion Pharmaceuticals | $20.16 | 2023 | Methylphenidate Hydrochloride |
| Ars Pharmaceuticals Operations, INC. | $18.08 | 2025 | Neffy |
| Mylan Pharmaceuticals INC. | $16.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Meikle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.